ABSTRACT Freshly isolated mononuclear leukocytes have been reported to-show changes in cholesterol synthesis and high-affinity degradation of low-density lipoproteins (LDL) that parallel those that occur in the liver. To examine whether hypolipidemic therapy in patients with heterozygous familial hypercholesterolemia influences cholesterol homeostasis in their mononuclear cells we assessed the effects of colestipol and nicotinic acid (alone and in combination) on the rates of high-affinity "SI-labeled LDL degradation and on the rates of cholesterol and phosphatidylcholine biosynthesis by freshly isolated cells. Rates of '25I-labeled LDL degradation were lower in mononuclear cells from patients with heterozygous familial hypercholesterolemia on no medication (3.1 ng per 4 X 106 cells per 5 hr) than in cells from normal control subjects (6.1 ng per 4 X 106 cells per 5 hr) and, in the former patients, the values were not significantly affected by therapy with nicotinic acid. In contrast, freshly isolated mononuclear cells from patients receiving colestipol degraded "2I-labeled LDL at nearnormal rates (5.0 ng per 4 x 106 cells per 5 hr). The rates of cholesterol synthesis were also higher in mononuclear cells isolated from patients treated with colestipol than in cells from untreated patients or from those receiving nicotinic acid; in contrast the rate of synthesis of phosphatidylcholine did not show any consistent changes. Similar results were obtained in a smaller number of patients studied longitudinally, in which colestipol therapy significantly increased rates of cholesterol synthesis and high-affinity degradation of '25I-labeled LDL by freshly isolated mononuclear cells. We conclude that previously observed changes in cholesterol homeostasis in the liver of patients treated with bile acid sequestrants are paralleled by similar changes in freshly isolated mononuclear cells and that these cells offer an accessible model for further studies on how diet and pharmacologic agents influence cellular cholesterol homeostasis in humans.
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Optimal treatment of patients with heterozygous familial hypercholesterolemia (FH) necessitates the use of diet and hypolipidemic medication, among which the bile acid-binding resins (colestipol and cholestyramine) and nicotinic acid are the most efficacious (1, 2) . Recent studies have clarified the mechanisms by which colestipol and cholestyramine decrease plasma concentrations of low-density lipoproteins (LDL) in both experimental animals and in humans (3, 4) . Both drugs bind bile acids in the intestinal lumen, thereby interrupting the enterohepatic circulation and stimulating an increase in the hepatic conversion of cholesterol to bile acids. This in turn depletes the hepatic pool of cholesterol and results in two compensatory changes; an increase in the de novo biosynthesis of cholesterol (5) has been shown in humans and an increase in the number of specific high-affimity LDL receptors on hepatocyte membranes has been shown in rabbits and dogs (4, 6) . The latter change also promotes an increase in the rate of catabolism of LDL (3), SO that overall the concentrations of this lipoprotein in plasma are decreased. In contrast, the hypolipidemic effect of nicotinic acid is thought to result primarily from a decrease in the rate of LDL production (7) with little change in the fractional rate of catabolism of LDL.
Combined drug therapy with colestipol and nicotinic acid is the most efficacious regimen currently available for maximally decreasing the concentrations of LDL cholesterol in patients with heterozygous FH (8) (9) (10) (11) . This regimen is presumed to act by a dual mechanism that affects both the synthesis (decreased by nicotinic acid) and catabolism (increased by colestipol) of LDL.
Recent studies have suggested that changes in the rate of synthesis of cholesterol in the liver may be accompanied by parallel changes in nonhepatic tissues such as mononuclear leukocytes (12) (13) (14) . To date, however, no data are available on whether such changes occur in freshly isolated mononuclear leukocytes from patients with heterozygous FH and whether these changes are paralleled by differences in the rates of uptake and degradation of LDL. In the present study, we have examined the effects of hypolipidemic therapy with diet, colestipol, and nicotinic acid (alone and in combination) on the rates of synthesis of cholesterol and phospholipids as well as the rates of high-affinity degradation of'I-labeled LDL by freshly isolated mononuclear leukocytes from patients with well characterized heterozygous FH. (17) . LDL was isolated by ultracentrifugation between the densities of 1.019 and 1.060 g/ml. The LDL thus obtained was washed one time by refloatation at a density of 1.060 g/ml and was then exhaustively dialyzed against 5 mM sodium phosphate/0.9% sodium chloride, pH 7.4. Protein was measured by the method of Hartree (18) and free and esterified cholesterol were determined by gas/liquid chromatography. Purified LDL was radiolabeled using the iodine monochloride method of McFarlane (19) as modified by Langer et al. (20) . Free 125I was removed by gel filtration on a Sephadex G50 column after which the "2I-labeled LDL was dialyzed exhaustively against [12] [13] [14] [15] liters of 5 mM sodium phosphate/0.9% sodium chloride, pH 7.4 and then filtered through a 0.45-,uM Millipore filter. The specific activity of the "2I-labeled LDL used in these experiments was between 250 and 500 dpm per ng of protein.
MATERIALS AND METHODS
Mononuclear Cell Studies. Mononuclear cells were isolated from 40-50 ml of heparinized whole blood by centrifugation on a Ficoll-Paque density gradient (21 13 11 Normal subjects 184 ± 4 113 ± 7 57 ± 2 69 ± 8 31 Values are mean ± SEM (mg/dl) forthe indicated number ofpatients (n) in each group. Chol, cholesterol. *P < 0.001 vs. diet only treatment group. tP < 0.05 vs. colestipol treatment.
ceiving single-drug therapy with nicotinic acid, total cholesterol values were 15.5% lower than in the FH patients on no hypolipidemic drugs. These changes in total cholesterol were accompanied by parallel but greater differences in the concentrations of LDL cholesterol ( Table 1) .
The rates of high-affinity degradation of "MI-labeled LDL by freshly isolated mononuclear cells from the patients with FH on diet therapy only ( Fig. 1) were significantly lower than those of normal subjects (3.1 vs. 6.1 ng per 4 x 106 cells per 5 hr). This result is in agreement with the earlier studies of Bilheimer et al. (22) and is consistent with the known metabolic abnormality in patients with familial hypercholesterolemia. In making this comparison it should be emphasized that the control subjects were studied on an ad lib diet, whereas the FH patients were habituated to a diet low in cholesterol and saturated fat. However, cholesterol feeding has been shown to decrease rates of "WI-labeled LDL degradation by freshly isolated mononuclear cells (14) from normolipidemic humans, and this suggests that differences in cholesterol intake between the control and FH patients should tend to decrease rather than increase the differences in high-affinity degradation of "2I-labeled LDL The studies of LDL degradation in freshly isolated mononuclear cells were complemented by parallel studies in which the rates of synthesis of cholesterol and phosphatidylcholine were examined (Fig. 2 and Table 2 ). The rates of cholesterol synthesis from [2-'4C]acetate were significantly (P < 0.05) higher in freshly isolated mononuclear cells from FH patients treated with colestipol than in patients on diet only. In contrast, the and rates of l2I5labeled LDL degradation represent the mean ± SEM for nine patients studied'sequentially; data for cholesterol synthesis representthe mean ± SEMforthree patients. Statistical analyses were by paired t test. Ac, acetate; Chol, cholesterol.
rates of cholesterol synthesis by freshly isolated mononuclear cells from FH patients receiving nicotinic acid as single-drug therapy were similar to those of patients on diet therapy alone (Fig. 2) . The rates of incorporation of [methyl-3H]choline into phosphatidylcholine by freshly isolated mononuclear cells from FH patients on various treatment regimens were not different ( Table 2 ) and suggest that the stimulatory effects of colestipol on LDL degradation and cholesterol synthesis were not mirrored by parallel increases in phosphatidylcholine biosynthesis.
Longitudinal studies in a smaller number of patients with heterozygous FH have confirmed the stimulatory effects of colestipol therapy on both cholesterol synthesis and rates of highaffinity degradation of "2I-labeled LDL by freshly isolated mononuclear cells (Table 3) . As in the cross-sectional study, significant differences were found in the rates of cholesterol synthesis (46 ± in the same patients studied sequentially under steady-state conditions on diet treatment only as compared to diet and colestipol.
DISCUSSION
Recent studies have suggested that freshly isolated mononuclear leukocytes respond to many of the factors known to affect cholesterol biosynthesis in the liver in vivo or in cultured cell lines in vitro. Young and Rodwell (12) documented parallel changes in the activity of hydroxymethylglutaryl-CoA reductase from freshly isolated leukocytes and hepatic tissue from rats fed cholesterol (a decrease in hydroxymethylglutaryl-CoA reductase) or cholestyramine (an increase in enzyme activity). McNamara et al. (13) have shown that this may also be true for freshly isolated human mononuclear cells. Rates of cholesterol biosynthesis in mononuclear cells from a heterogeneous group of patients with hyperlipidemia were found to be 2 times higher when obtained from subjects receiving cholestyramine than in cells from control subjects or other hyperlipidemic patients treated with clofibrate. These changes parallel the increase in cholesterol synthesis previously observed in the liver of patients treated with cholestyramine (23) . The feeding of cholesterol to human volunteers has been reported to result in parallel decreases in the activity of hydroxymethylglutaryl-CoA reductase and in LDL receptor activity in freshly isolated mononuclear cells (14) . Similarly, treatment of diabetics with insulin leads to an increase in "2I-labeled LDL degradation by their freshly isolated mononuclear cells (24) . Overall, these studies suggest that comparative changes in cholesterol synthesis and in the rates of high-affinity degradation of LDL by freshly isolated mononuclear leukocytes from patients on different diet and drug regimens may parallel those that occur in the liver. The results of the present study provide evidence that hypolipidemic therapy with colestipol but not with nicotinic acid leads to an increase in the rates of cholesterol synthesis and high-affinity LDL degradation by freshly isolated mononuclear cells from patients with heterozygous FH.
The mechanism(s) by which bile acid sequestrants, which are not absorbed, may influence the rates of cholesterol synthesis and high-affinity LDL degradation in mononuclear cells is unknown. In the present study and in that of McNamara et al. (13) no correlation was found between the rates of sterol synthesis in freshly isolated mononuclear cells and the concentrations of LDL in plasma. Studies in other model systems, however, suggest that decreases in the cellular concentration of cholesterol (25, 26) , or possibly an increase in the sphingomyelin content (27) , result in compensatory increases in cholesterol synthesis and usually, but not invariably (27) , the number of LDL receptors. Cholesterol homeostasis in freshly isolated mononuclear cells may potentially be influenced by several factors including variations in the composition of LDL (28) or changes in the distribution of LDL within different subfractions (29, 30) , both of which may be influenced by the residence time of LDL in plasma as well as by variations in the concentrations of several hormones known to influence lipid metabolism.
Several investigators have reported differences in the composition of LDL isolated from the plasma of patients with familial hypercholesterolemia as compared with those of normolipidemic control subjects (31-33). These differences include an increase in the cholesterol/phospholipid ratio, an increase in the proportion of cholesterol esters, and an abnormally low lecithin/sphingomyelin ratio. These acquired changes, which are believed to reflect decreases in the fractional rate of catabolism of LDL, are more pronounced in patients with homozygous FH and can be partially ameliorated by plasma exchange therapy or by treatment with colestipol or cholestyramine (31) . Although increases in the cholesterol ester and sphingomyelin content of LDL have been reported to decrease its binding affinity to the high-affinity LDL receptors on cultured human fibroblasts (34) , an earlier study (35) showed no difference in the rates of cellular metabolism of LDL isolated from the plasma of normal subjects as compared with that from patients with homozygous FH. Thus, it is unclear whether the higher rates of high-affinity LDL degradation and the increases in cholesterol biosynthesis by freshly isolated mononuclear cells from patients treated with colestipol, which were observed in the present study, are related to changes in LDL composition that result from an increased fractional catabolic rate of this lipoprotein.
In summary, our results provide evidence that the rates of cholesterol biosynthesis and high-affinity degradation of LDL by freshly isolated mononuclear cells from patients with heterozygous FH can be stimulated by treatment with colestipol and, therefore, show changes that parallel those known to occur in the liver. These observations also suggest that freshly isolated mononuclear cells are not an appropriate tool with which to biochemically diagnose heterozygous FH if the cells are taken from a patient on certain hypolipidemic medication, specifically the bile acid sequestrants. Because of their accessibility, freshly isolated mononuclear cells provide a useful model system in which the effects of hypolipidemic medications or different dietary constituents on cellular cholesterol homeostasis can be evaluated in humans.
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